|
1
|
Rumgay H, Ferlay J, de Martel C, Georges
D, Ibrahim AS, Zheng R, Wei W, Lemmens VEPP and Soerjomataram I:
Global, regional and national burden of primary liver cancer by
subtype. Eur J Cancer. 161:108–118. 2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Trépo C, Chan HL and Lok A: Hepatitis B
virus infection. Lancet. 384:2053–2063. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Global Burden of Disease Cancer
Collaboration. Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, mortality, years
of life lost, years lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tong S and Revill P: Overview of hepatitis
B viral replication and genetic variability. J Hepatol. 64 (1
Suppl):S4–S16. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
European Association for the Study of the
Liver. Electronic address: simpleeasloffice@easloffice.eu;
European Association for the Study of the Liver. EASL 2017 clinical
practice guidelines on the management of hepatitis B virus
infection. J Hepatol. 67:370–398. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Terrault NA, Lok ASF, McMahon BJ, Chang
KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH and Wong JB: Update
on prevention, diagnosis, and treatment of chronic hepatitis B:
AASLD 2018 hepatitis B guidance. Hepatology. 67:1560–1599.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Marcellin P, Gane E, Buti M, Afdhal N,
Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF,
Aguilar Schall R, et al: Regression of cirrhosis during treatment
with tenofovir disoproxil fumarate for chronic hepatitis B: A
5-year open-label follow-up study. Lancet. 381:468–475.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hosaka T, Suzuki F, Kobayashi M, Seko Y,
Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, et al:
Long-term entecavir treatment reduces hepatocellular carcinoma
incidence in patients with hepatitis B virus infection. Hepatology.
58:98–107. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nguyen MH, Yang HI, Le A, Henry L, Nguyen
N, Lee MH, Zhang J, Wong C, Wong C and Trinh H: Reduced Incidence
of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients
With Chronic Hepatitis B Treated With Tenofovir-A Propensity
Score-Matched Study. J Infect Dis. 219:10–18. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kumada T, Toyoda H, Tada T, Kiriyama S,
Tanikawa M, Hisanaga Y, Kanamori A, Niinomi T, Yasuda S, Andou Y,
et al: Effect of nucleos(t)ide analogue therapy on
hepatocarcinogenesis in chronic hepatitis B patients: A propensity
score analysis. J Hepatol. 58:427–433. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Papatheodoridis GV, Chan HL, Hansen BE,
Janssen HL and Lampertico P: Risk of hepatocellular carcinoma in
chronic hepatitis B: Assessment and modification with current
antiviral therapy. J Hepatol. 62:956–967. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lampertico P, Maini M and Papatheodoridis
G: Optimal management of hepatitis B virus infection-EASL special
conference. J Hepatol. 63:1238–1253. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Papatheodoridis G, Dalekos G, Sypsa V,
Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S,
Mangia G, et al: PAGE-B predicts the risk of developing
hepatocellular carcinoma in Caucasians with chronic hepatitis B on
5-year antiviral therapy. J Hepatol. 64:800–806. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wong VWS and Janssen HLA: Can we use HCC
risk scores to individualize surveillance in chronic hepatitis B
infection? J Hepatol. 63:722–732. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Marrero JA, Fontana RJ, Fu S, Conjeevaram
HS, Su GL and Lok AS: Alcohol, tobacco and obesity are synergistic
risk factors for hepatocellular carcinoma. J Hepatol. 42:218–224.
2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tada T, Kumada T, Toyoda H, Tsuji K,
Hiraoka A and Tanaka J: Impact of FIB-4 index on hepatocellular
carcinoma incidence during nucleos(t)ide analogue therapy in
patients with chronic hepatitis B: An analysis using time-dependent
receiver operating characteristic. J Gastroenterol Hepatol.
32:451–458. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tseng TC, Choi J, Nguyen MH, Peng CY,
Siakavellas S, Papatheodoridis G, Wang CC, Lim YS, Lai HC, Trinh
HN, et al: One-year fibrosis-4 index helps identify minimal HCC
risk in non-cirrhotic chronic hepatitis B patients with antiviral
treatment. Hepatol Int. 15:105–113. 2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yang HI, Yuen MF, Chan HL, Han KH, Chen
PJ, Kim DY, Ahn SH, Chen CJ, Wong VW and Seto WK: REACH-B Working
Group. Risk estimation for hepatocellular carcinoma in chronic
hepatitis B (REACH-B): Development and validation of a predictive
score. Lancet Oncol. 12:568–574. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wong VW, Chan SL, Mo F, Chan TC, Loong HH,
Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, et al: Clinical scoring
system to predict hepatocellular carcinoma in chronic hepatitis B
carriers. J Clin Oncol. 28:1660–1665. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yuen MF, Tanaka Y, Fong DY, Fung J, Wong
DK, Yuen JC, But DY, Chan AO, Wong BC, Mizokami M and Lai CL:
Independent risk factors and predictive score for the development
of hepatocellular carcinoma in chronic hepatitis B. J Hepatol.
50:80–88. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Vallet-Pichard A, Mallet V, Nalpas B,
Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H and Pol S:
FIB-4: An inexpensive and accurate marker of fibrosis in HCV
infection. Comparison with liver biopsy and fibrotest. Hepatology.
46:32–36. 2007.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Drafting Committee for Hepatitis
Management Guidelines, the Japan Society of Hepatology. Japan
society of hepatology guidelines for the management of hepatitis B
virus infection: 2019 Update. Hepatol Res. 50:892–923.
2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kobashi H, Miyake Y, Ikeda F, Yasunaka T,
Nishino K, Moriya A, Kubota J, Nakamura S, Takaki A, Nouso K, et
al: Long-term outcome and hepatocellular carcinoma development in
chronic hepatitis B or cirrhosis patients after nucleoside analog
treatment with entecavir or lamivudine. Hepatol Res. 41:405–416.
2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Köklü S, Tuna Y, Gülşen MT, Demir M,
Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, et al:
Long-term efficacy and safety of lamivudine, entecavir, and
tenofovir for treatment of hepatitis B virus-related cirrhosis.
Clin Gastroenterol Hepatol. 11:88–94. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tacke F and Kroy DC: Treatment for
hepatitis B in patients with drug resistance. Ann Transl Med.
4(334)2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Papatheodoridis GV, Lampertico P,
Manolakopoulos S and Lok A: Incidence of hepatocellular carcinoma
in chronic hepatitis B patients receiving nucleos(t)ide therapy: A
systematic review. J Hepatol. 53:348–356. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Schafer DF and Sorrell MF: Hepatocellular
carcinoma. Lancet. 353:1253–1257. 1999.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Okuda K: Hepatocellular carcinoma. J
Hepatol. 32 (1 Suppl):S225–S237. 2000.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kim JH, Kim JW, Seo JW, Choe WH and Kwon
SY: Noninvasive tests for fibrosis predict 5-year mortality and
hepatocellular carcinoma in patients with chronic hepatitis B. J
Clin Gastroenterol. 50:882–888. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Suh B, Park S, Shin DW, Yun JM, Yang HK,
Yu SJ, Shin CI, Kim JS, Ahn E, Lee H, et al: High liver fibrosis
index FIB-4 is highly predictive of hepatocellular carcinoma in
chronic hepatitis B carriers. Hepatology. 61:1261–1268.
2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Cho JY, Paik YH, Sohn W, Cho HC, Gwak GY,
Choi MS, Lee JH, Koh KC, Paik SW and Yoo BC: Patients with chronic
hepatitis B treated with oral antiviral therapy retain a higher
risk for HCC compared with patients with inactive stage disease.
Gut. 63:1943–1950. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zoutendijk R, Reijnders JG, Zoulim F,
Brown A, Mutimer DJ, Deterding K, Hofmann WP, Petersen J, Fasano M,
Buti M, et al: Virological response to entecavir is associated with
a better clinical outcome in chronic hepatitis B patients with
cirrhosis. Gut. 62:760–765. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu
SN, Huang GT and Iloeje UH: REVEAL-HBV Study Group. Risk of
hepatocellular carcinoma across a biological gradient of serum
hepatitis B virus DNA level. JAMA. 295:65–73. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chen G, Lin W, Shen F, Iloeje UH, London
WT and Evans AA: Past HBV viral load as predictor of mortality and
morbidity from HCC and chronic liver disease in a prospective
study. Am J Gastroenterol. 101:1797–1803. 2006.PubMed/NCBI View Article : Google Scholar
|
|
36
|
European Association for the Study of the
Liver. Electronic address: simpleeasloffice@easloffice.eu;
European Association for the Study of the Liver. EASL clinical
practice guidelines: Management of hepatocellular carcinoma. J
Hepatol. 69:182–236. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Oze T, Hiramatsu N, Yakushijin T, Miyazaki
M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, et al:
Post-treatment levels of α-fetoprotein predict incidence of
hepatocellular carcinoma after interferon therapy. Clin
Gastroenterol Hepatol. 12:1186–1195. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Tada T, Kumada T, Toyoda H, Kiriyama S,
Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T and Tanaka
J: Post-treatment levels of α-fetoprotein predict long-term
hepatocellular carcinoma development after sustained virological
response in patients with hepatitis C. Hepatol Res. 47:1021–1031.
2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kuwano A, Yada M, Nagasawa S, Tanaka K,
Morita Y, Masumoto A and Motomura K: Serum α-fetoprotein level at
treatment completion is a useful predictor of hepatocellular
carcinoma occurrence more than one year after hepatitis C virus
eradication by direct-acting antiviral treatment. J Viral Hepat.
29:35–42. 2022.PubMed/NCBI View Article : Google Scholar
|
